Compare CLST & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CLST | SERA |
|---|---|---|
| Founded | 1922 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Precision Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 66.6M | 75.2M |
| IPO Year | 2021 | 2021 |
| Metric | CLST | SERA |
|---|---|---|
| Price | $16.59 | $2.05 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 2.2K | ★ 37.7K |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 171.79 | 32.32 |
| EPS | ★ 0.15 | N/A |
| Revenue | N/A | ★ $81,000.00 |
| Revenue This Year | N/A | $554.81 |
| Revenue Next Year | N/A | $517.27 |
| P/E Ratio | $110.07 | ★ N/A |
| Revenue Growth | N/A | ★ 5.19 |
| 52 Week Low | $12.25 | $1.56 |
| 52 Week High | $18.16 | $3.95 |
| Indicator | CLST | SERA |
|---|---|---|
| Relative Strength Index (RSI) | 57.31 | 55.89 |
| Support Level | $16.40 | $1.85 |
| Resistance Level | $16.98 | $2.40 |
| Average True Range (ATR) | 0.21 | 0.14 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 44.00 | 81.01 |
Catalyst Bancorp Inc is a bank holding company. Through its subsidiary, which is a federally chartered community-oriented savings bank, it is engaged in attracting deposits from the general public and using those funds to invest in loans and securities. The sources of funds are customer deposits, repayments of loans, maturities of investments, and funds borrowed from outside sources, which are used for the origination of loans. It operates in one reportable segment, which generates income principally from interest on loans and investment securities, as well as from fees charged in connection with various loan and deposit services.
Sera Prognostics Inc is a health diagnostic company. It is a women's health company utilizing the proprietary proteomics and bioinformatics platform, and data resources to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.